Back
Compare AU
Compare GGUS vs. CURE
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the Betashares Geared Us Eqty Ccy Hedged Complex ETF (GGUS) and the Global X S&P Biotech ETF (CURE). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
GGUS | CURE | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 295 | 68 |
Median incremental investment | $1,106.94 | $666.25 |
Median investment frequency | Monthly | Monthly |
Median total investment | $3,397.68 | $2,072.32 |
Average age group | > 35 | > 35 |
Key Summary
GGUS | CURE | |
|---|---|---|
Strategy | GGUS.AX was created on 2015-08-17 by BetaShares. The fund's investment portfolio concentrates primarily on large cap equity. The Fund provides investors with a simple way to obtain a cost-effective geared exposure to the returns of the U.S. sharemarket, hedged to Australian Dollars. | CURE.AX was created on 2018-11-08 by Global X. The fund's investment portfolio concentrates primarily on health care equity. The ETF currently has 41.75m in AUM and 146 holdings. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the S&P Biotechnology Select Industry Index. |
Top 3 holdings | ISHARES CORE S&P 500 ETF (201.77 %) AUD - AUSTRALIA DOLLAR (101.10 %) USD - UNITED STATES DOLLAR (-202.87 %) | Revolution Medicines Inc Ordinary Shares (1.82 %) Moderna Inc (1.81 %) Praxis Precision Medicines Inc Ordinary Shares (1.51 %) |
Top 3 industries | Other (83.88 %) Communication Services (16.12 %) | Health Care (100.00 %) Other (10.24 %) |
Top 3 countries | United States (99.40 %) Switzerland (0.28 %) Netherlands (0.13 %) | United States (97.17 %) Switzerland (1.51 %) United Kingdom of Great Britain and Northern Ireland (1.16 %) |
Management fee | 0.8 % | 0.45 % |
Key Summary
GGUS | CURE | |
|---|---|---|
Issuer | BetaShares | Global X |
Tracking index | S&P Biotechnology Select Industry | |
Asset class | ETF | ETF |
Management fee | 0.8 % | 0.45 % |
Price | $51.94 | $65.95 |
Size | $358.618 million | $43.000 million |
10Y return | 572.80 % | N/A |
Annual distribution yield (5Y) | 2.26 % | 5.08 % |
Market | ASX | ASX |
First listed date | 18/08/2015 | 12/11/2018 |
Purchase fee | $6.50 | $6.50 |
Community Stats
GGUS | CURE | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 295 | 68 |
Median incremental investment | $1,106.94 | $666.25 |
Median investment frequency | Monthly | Monthly |
Median total investment | $3,397.68 | $2,072.32 |
Average age group | > 35 | > 35 |
Pros and Cons
GGUS | CURE | |
|---|---|---|
Pros |
|
|
Cons |
|
|
GGUS | CURE |
|---|---|
Higher exposure to US market | Lower exposure to US market |
Higher management fee | Lower management fee |
Higher price growth | Lower price growth |
Lower distribution yield | Higher distribution yield |